The US firm has added capacity for ELISA, SDS-PAGE, Western blots, image analysis, HPLC, HPLC-MS, ligand-receptor binding assays, cellular proliferation, cytotoxicity and cellular activation assays to its range of biopharmaceutical services.
Spokesman Robert Becker told BioPharma-Reporter.com “The expansion was motivated by both demand from existing customers for analysis and from ongoing discussions with firms interested in our services.”
He went on to say that: “Adding cell culture and extensive instrumentation to support the testing and characterizations of these biopharmaceuticals was planned for later this year but we've accelerated implementation to meet our client's needs."
“We see a lot of potential in the market for biopharmaceutical analysis services both for biologicals and vaccines.”
Becker explained that Particle Sciences has been rapidly expanding its biopharmaceutical analysis services and that the business is organised into two key areas.
“We help customers better characterise the proteins and other large molecules they produce,” he said, adding that “we also provide testing services that measure the biological activity of the compounds in question.”
Becker added that Particle Sciences’ in-house team includes skilled biopharmaceutical analysis technicians and said that the intention is to increase headcount as the business continues to expand.
The new analysis technologies – which have been installed at Particle Sciences’ facility in Bethlehem, Pennsylvania, US – will also be used to cater for customers developing small molecule pharmaceuticals.
News of the investment comes a little over a month after Particle Sciences teamed up with Microfluidics in an agreement driven by customer demand for advanced formulation development services.